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CD13 AG and CD11a, CD11b, CD18 molecule expres-
sion on peripheral blood mononuclear cells (PBMC)
were studied as these cells’ adherent or transendothe-
lial migration properties in three different multiple
sclerosis (MS) patients groups (total 38): with clini-
cally active MS (acute exacerbation of MS and primary
chronic progressive MS (CP-MS)) and with MS remis-
sion. The control group consisted of patients, suffer-
ing  from  other  non-inflammatory  neurological  dis-
eases  (OND).  The  results  of  our  study  suggest  that
CD11a/CD18  molecules  expression  on  PB  lympho-
cytes, although higher on these cells’ surface in the
course of MS as compared to OND, does not differ-
entiate clinical forms of MS. CD11a molecule expres-
sion on monocytes did not differ significantly in all
tested  MS  patient  groups  in  comparison  to  OND.
Although the expression of  CD11b/CD18 molecules
on monocytes’ surface shows their activation in the
course  of  MS,  it  does not  differentiate them  either.
However,  CD13  Ag  of  APN  expression  on  PBMC
surface  may  be  an  immunological  marker  of  MS
clinical  form.  CD13  Ag  expression  may  also  be  a
sensitive  marker  of  these  cells’  transendothelial
migration properties.
Key words: Multiple sclerosis, Lymphocytes, Monocytes,
LFA-1, Mac-1, APN
Introduction
Multiple  sclerosis  (MS)  is  a  primary  demyelinating
disease in which the blood–brain barrier (BBB) damage
and mononuclear cells’ infiltration  in active plaques
within  the  central  nervous  system  (CNS)  represent
characteristic pathologic features. Inflammatory pro-
cesses in CNS may be initiated by activated peripheral
blood mononuclear cells (PBMC).1 They can migrate
through BBB and enable development of MS itself and
its clinical acute exacerbation. Such a disease evolution
is based on the animal model of allergic encephalomye-
litis (EAE). In the course of clinically active MS, the
migration  of  PBMC  through  the  BBB  could  be
secondary to the local BBB disruption by inflammatory
cytokines and extracellular matrix degrading proteases
produced  in  plaques  in  CNS,  and  thus without the
involvement of PBMC.2These create a totally different
view on the disease immunopathology. The problem of
whether PMNL can show adherent and transendothe-
lial  migration  properties  in  the  course  of  clinically
active MS could be solved indirectly by evaluation of
the b -integrin molecule expression and extracellular
matrix degrading proteases production by these cells.
The molecule expression on PBMC may also ‘immuno-
logically’ differentiate clinical periods of MS.
Material and methods
There were three groups of patients (total 38) aged
21–56 years (mean 38.2 ± 10.1 years) with clinically
definite MS and with Expanded Disability Status Scale
scores of 5 or lower. Thirteen patients (seven women
and  six  men)  were  examined  during  the course  of
acute  MS  exacerbation,  12  patients  (seven  women
and five men) with primary chronic progressive MS
(CP-MS) and 13 patients (six women and seven men)
during  MS  remission.  The  control  group  (OND)
consisted  of  14  patients  (seven  women  and  seven
men),  aged  22–41  years  (mean  31.3  ±  6.7  years),
suffering from other neurological diseases, like vaso-
motor headache in 10 and epilepsy in four cases.
Immunostaining and FACS analysis
Blood  samples  were  obtained  in  the  morning
between  8.00  and  9.00  a.m. by  venipuncture.  One
hundred  microlitres  of  blood  was  mixed  and  incu-
bated  at  room  temperature  with  appropriate  quan-
tities of monoclonal antibodies anti- CD11a,  CD11b
and  CD18  provided  by  Dako  (Denmark). A  double-
step staining procedure was used for the evaluation of
CD13  Ag  expression.  Mouse  immunoglobulin  anti-
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1CD13  (Dako)  was  used  as  a  first  step.  Rabbit  anti-
mouse polyclonal IgG  stained with R-phycoerythrin
was used as a secondary antibody. The rabbit IgG was
also  used  as  a  negative  control.  Erythrocytes  were
eliminated by an addition of lysing solution (Becton
Dickinson) into  the blood samples. A  FACscan  flow
cytometer with a 488-nm argon laser (Becton Dick-
inson)  and  Lysis  II  software were  used. The  results
were expressed as the values of mean fluorescence
intensity (MFI) of the labelled surface antigens.
An example of CD13 Ag expression on peripheral
blood lymphocytes is shown on Fig. 1.
The obtained results were analysed, using Student’s
t-test and the Cochran–Cox rank test.
Results
The expression of CD11a/CD18  molecules of LFA-1
integrine was higher on lymphocytes in the course of
clinically active MS (MS acute exacerbation and in CP-
MS) as well as in MS remission comparing to the OND
group (Table 1). Among MS patients the expression of
LFA-1 molecules on lymphocytes surface did not differ
significantly.
CD11a molecule expression on monocytes did not
differ significantly in all the tested MS patient groups
in comparison to the OND. The CD11b molecule of
Mac-1  integrine  expression  was  significantly  higher
on monocytes in  the course of MS acute exacerba-
tions  and  in  CP-MS compared  to MS  remission  and
OND.  CD11b  expression  was  also  higher  in  the
course of MS remission compared to the OND group.
Similarly  to  CD11b  molecule  expression  on  mono-
cytes, the differences were noticed in molecule CD18
expression.
Conversely to the integrines molecule expression
on PBMC, CD13 Ag expression on lymphocytes and
on  monocytes ‘immunologically’  differentiated  clin-
ical  periods  of  MS.  In  the  course  of  MS  acute
exacerbation and in CP-MS groups, it was significantly
enhanced in comparison to MS remission and OND
(Table 1).
Discussion
The mechanisms of PBMC migration through the BBB
in the course of MS are not yet known. In a series of
repeated tests, higher b 1 and b 2 integrin molecules’
expression on CD4+T-cells in acute MS exacerbation
compared to MS remission was not found.3 Also, in
our  observations  LFA-1  and  Mac-1  integrine  mole-
cules’ expression on PBMC did not ‘immunologically’
differentiate transendothelial migration properties of
PBMC  in  the course  of MS. However, CD11a/CD18
molecules’  expression  on  PB  lymphocytes,  in  each
group  of  MS  patients,  was  higher  than  in  OND
patients.  In  our  opinion  this  could  suggest  an
increased percentage of memory cells in the periph-
eral blood of all the MS patients. This was also shown
in  some  other  studies.4 It  indirectly  suggests  that
circulating  lymphocytes  in  MS  are  predisposed  to
cross  endothelial  barriers. Also  CD11b/CD18  mole-
cules of Mac-1 integrine expression were higher on
monocytes’ surface in the course of clinically active
MS compared to MS remission. This can be an effect of
non-specific  stimulation  of  CD11b/CD18  molecules
on these cells’ surfaces by immunological complexes,
or C3a and C5a. However Mac-1 has a much smaller
effect on monocyte adherence to endothelium than
LFA-1.5 Thus,  it  cannot  be  a  marker  of  monocyte
transendothelial migration in the course of MS.
Conversely  to  integrine  molecules,  CD13  Ag
expression  on  the  PBMC  surface  can  be  such  a
marker. CD13 Ag assessment is widely applied in the
evaluation of APN expression on PBMC surface.6 APN
is  a  zinc-dependent  metalloproteinase.  Similarly  to
92 kDa  gelatinase it  hydrolyses  the  IV-type  of  colla-
gen.7 Therefore, it plays an important role in PBMC
migration  across  the  blood  vessels.  Several  studies
revealed  a  crucial  role  of  92kDa  gelatinase  and
dipeptydyl-peptidase-IV  in  these  processes  in  the
course of MS.8,9 The results of our study suggest than
APN may also participate in it.
We have shown the presence of acivated PBMC in
the peripheral blood of MS patients. In the course of
acute exacerbation and in CP-MS, these cells show a
potentially greater ability to cross the BBB. The data
obtained may suggest that PBMC might play an active
role in BBB disruption in the course of MS.
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